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IS COMPLETE SYSTEMATIC NODAL DISSECTION BY THORACOSCOPIC SURGERY POSSIBLE? 
A PROSPECTIVE TRIAL OF VIDEO-ASSISTED LOBECTOMY FOR CANCER OF THE RIGHT LUNG
Takashi Kondo, MD, Motoyasu Sagawa, MD, Tatsuo Tanita, MD, Masami Sato, MD, Sadafumi Ono, MD, Yuji Matsumura,
MD, and Shigefumi Fujimura, MD, Sendai, Japan
Recently, video-assisted thoracic surgery (VATS) has been
widely applied to various intrathoracic benign diseases. The
procedure is apparently less invasive than any other conven-
tional standard thoracotomy and is also cosmetically pleasing
to patients. If VATS can be applied to the treatment of prima-
ry lung cancer, numerous benefits for patients can be expect-
ed, even if a small thoracotomy is needed to complete the pul-
monary resection. However, one problem remains in the
application of the procedure for surgical treatment of prima-
ry lung cancer, that is, the possibility of incomplete system-
atic nodal dissection. To clarify the feasibility of sufficient
dissection with VATS, we conducted a prospective clinical
trial in 6 patients with clinical stage I cancer of the right lung.
Patients and methods. Patients with stage I cancer of the
right lung were chosen for the present assessment because the
upper mediastinal and pretracheal nodes can be dissected with-
out the difficulty that is encountered in cancer of the left lung.
Inasmuch as this is the first trial, cases in which bronchoplasty
or angioplasty was anticipated were excluded. The present
study was approved by our institutional review board and com-
plete informed consent on this trial of thoracoscopy for surgi-
cal treatment of lung cancer was obtained from each patient.
With a small skin incision 7 to 8 cm in length, the right fifth
intercostal space was entered just below the lower angle of
the scapular bone. Respiratory muscles and ribs were not sev-
ered. Two additional thoracoports were placed in the fourth
and seventh intercostal spaces at the anterior and mid to pos-
terior axillary lines, respectively. Through the small wound
and the 2 thoracoports, a designated pulmonary lobe(s) was
resected with hilar and mediastinal lymph node dissection
(VATS lobectomy with lymph node dissection). In most
cases, the pulmonary vein and bronchus were transected with
staplers and branches of pulmonary artery were ligated and
transected through the small thoracotomy wound. After VATS
lobectomy with lymph node dissection, a standard thoracoto-
my was subsequently carried out by a different surgeon to
complete systematic nodal dissection.
At VATS lobectomy, the number of dissected lymph nodes
at each station and the weight of dissected tissues including
fat tissue were recorded. The location and the number of
remaining lymph nodes and the weight of dissected tissues
found at additional thoracotomy were recorded as well. Per-
cent of remaining nodes was calculated both for number and
for weight. Operating time required for VATS lobectomy with
lymph node dissection and the amount of bleeding during the
procedure were also recorded.
Results. To date, 6 patients have been treated. The primary
lesion was located in the upper lobe in 5 patients and in the
middle lobe in the other patient. Upper lobectomy was per-
formed in 4 patients and upper and middle lobectomy in 2
patients. Clinical stage was T1 N0 M0 in all patients (Table I).
From the Department of Thoracic Surgery, Institute of Development,
Aging and Cancer, Tohoku University, Sendai, Japan.
Received for publication June 4, 1998; accepted for publication June
9, 1998.
Address for reprints: Takashi Kondo, MD, Department of Thoracic
Surgery, Institute of Development, Aging and Cancer, Tohoku
University, 4-1 Seiryomachi Aobaku, Sendai 980-8575, Japan.
J Thorac Cardiovasc Surg 1998;116:651-2
Copyright © 1998 by Mosby, Inc.
0022-5223/98 $5.00 + 0 12/54/92470
Table I. Profile of patients and the disease state in the
present study
Primary Operative 
site Pathology cTNM procedure
1 (71, M) Upper lobe Adenocarcinoma T1 N0 M0 RUML
2 (68, F) Upper lobe Adenocarcinoma T1 N0 M0 RUL
3 (60, F) Upper lobe Adenocarcinoma T1 N0 M0 RUML
4 (68, F) Upper lobe Adenocarcinoma T1 N0 M0 RUL
5 (79, F) Middle lobe Adenocarcinoma T1 N0 M0 RML
6 (76, F) Upper lobe Adenocarcinoma T1 N0 M0 RUL
RUML, Right upper and middle lobectomy; RUL, right upper lobectomy;
RML, right middle lobectomy.
The time required for VATS lobectomy with lymph node
dissection was 140 to 260 minutes and the amount of bleeding
was 50 to 165 g (Table II). The average operating time and the
amount of bleeding were 213 minutes and 98 g, respectively.
The postoperative course was uneventful in all patients.
The number of dissected lymph nodes by VATS lobectomy
was 27 to 48, and remaining lymph nodes were found in 2
patients at additional thoracotomy. The weight of dissected
tissue by VATS lobectomy was 5.0 to 16.1 g. In the 2 patients
in whom remaining lymph nodes were found at subsequent
standard thoracotomy, the weight of the additionally dissect-
ed tissue was 0.6 and 0.2 g and the percentage of lymph nodes
remaining was 3.5% and 2%, respectively (Table II). Overall
percentage of nodes remaining after systematic nodal dissec-
tion by VATS lobectomy was 3.4% according to the number
and 1.5% according to the weight.
Discussion. Recent advances and improvements in devices
and equipment for endoscopic surgery enabled us to extend
its application to various disorders, not only benign condi-
tions but malignant diseases as well. Recently, several reports
have described the application of VATS to the early stages of
primary lung cancer.1,2 Although standard and VATS proce-
dures have yielded equivalent survivals,3 the absolute indica-
tions for VATS for patients with lung cancer have yet to be
defined, because no scientific studies on the validity of the
procedure for systematic nodal dissection in primary lung
cancer have been reported. In this study, residual lymph
nodes were found after the VATS procedure in 2 of 6 patients;
however, the number and the weight of those nodes were
unexpectedly small. Operative time and the amount of bleed-
ing with the VATS procedure were not unreasonable when
compared with the standard procedure.
Several techniques for VATS lobectomy have been presented
to date.4,5 The axillary approach has been commonly used in
these previous reports. Although this approach is useful in
dissecting hilar structures, it does not seem to be suitable for
mediastinal lymph node dissection, especially for dissecting
subcarinal nodes. In this study, we have chosen the posterior
approach for the small thoracotomy. From our experiences,
the subcarinal, pretracheal, and highest mediastinal lymph
nodes were easily dissected through this approach. In addi-
tion, no special devices for thoracoscopic surgery were nec-
essary to perform nodal dissection because of the short dis-
tance between the small thoracotomy incision and the
mediastinum and the direct visibility of the mediastinum
through the incision. Complete en bloc systematic nodal dis-
section was possible with ordinary surgical devices using the
present procedure in a right-sided operation.
Thus we conclude that the standard lobectomy with sys-
tematic nodal dissection for cancer of the right lung is tech-
nically feasible and can be performed safely through a small
thoracotomy with the aid of thoracoscope. The present pro-
cedure can be applied to cancer of the right lung that meets
the indications for standard surgical techniques.
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Table II. Time needed for VATS procedure and amount of bleeding during VATS; number of lymph nodes resected
by VATS and number and location of residual lymph nodes found at subsequent standard thoracotomy; weight of
dissected and residual tissues, including lymph nodes, resected by VATS
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Operating time (min) 260 190 250 140 200 240
Blood loss (g) 140 70 165 100 50 65
No. of lymph nodes
VATS dissection 43 27 28 37 48 46
Subsequent standard dissection 6 0 0 0 0 2
Remaining lymph nodes No. 11, No. 3* — — — — No. 9
Weight of dissected and residual
tissues
VATS (g) 16.1 5.4 8.9 5.0 8.0 9.8
Subsequent standard dissection 0.6 0 0 0 0 0.2
Remaining lymph nodes (%) 3.5 0 0 0 0 2.0
*Retrotracheal node.
